Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04965842 monotherapy for moderate to severe atopic dermatitis in patients aged 12 years and older
2017-003651-29Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing PF-04965842 monotherapy with Placebo (2 arms). Primary endpoint: Investigator's Global Assessment response at Week 12. Started Jan 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2017-003651-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003651-29.